MPC Therapeutics supported by MATWIN in 2022 and awarded by MATWIN International Board for the “Best Technological Innovation” announces completion of its CHF 1.5M seed-funding round to improve CAR-T cancer therapies.
Read the press release : https://www.linkedin.com/feed/update/urn:li:activity:7018827677285392384/
